Cramer's Morning Take: Eli Lilly 5/22/25

SPEAKER_1 (0:00)

Hey, Fidelity, what's it cost to invest with the Fidelity app? Start with as little as one dollar, with no account fees or trade commissions on US stocks and ETFs.

Conan O'Brien (0:11)

Hmm, that's music to my ears.

SPEAKER_1 (0:14)

I can only talk.

SPEAKER_3 (0:17)

Investing involves risk, including risk of loss. Zero account fees apply to retail brokerage accounts only. Zero dollar commission applies to online US equity trades and ETFs and retail Fidelity accounts.

SPEAKER_4 (0:23)

Sell order assessment fee not included.

SPEAKER_3 (0:24)

Some account types and securities excluded. Details at fidelity.com/commissions.

SPEAKER_1 (0:26)

Fidelity Brokerage Services LLC, member NYSE SIPC.

SPEAKER_4 (0:31)

Are you still quoting 30 year old movies? Have you said cool beans in the past 90 days? Do you think Discover isn't widely accepted? If this sounds like you, you're stuck in the past. Discover is accepted at 99% of places that take credit cards nationwide. And every time you make a purchase with your card, you automatically earn cash back. Welcome to the now. It pays to discover. Learn more at discover.com/creditcardbased on the February 2024 Nelson report.

Jim Cramer (1:00)

Jim Cramer here to share with you a sample of my take on the market from today's CNBC Investing Club morning meeting.

SPEAKER_3 (1:09)

Well, look, healthcare as a sector, call it the struggles of UNH, some concerns about pharma. Healthcare has been very disappointing this year.

Jim Cramer (1:18)

Yes, it has.

SPEAKER_3 (1:18)

Big surprise. I was a little bit more optimistic on healthcare. Coming into the year, it hasn't worked out. Even Eli Lilly, which had been doing so well, especially when we had the good pill data just the other week, has now come all the way back down.

Jim Cramer (1:33)

I'm really glad you mentioned Eli Lilly. I've got Dr. Eric Topol on tonight, who's an incredible, well-respected cardiologist, who's written some books. And he has come out with an unqualified endorsement of the GLP-1. He's on tonight, and I'm going to talk about it, for all sorts of things, far more than diabetes and weight. He even speculates, maybe everybody has to take it. So I think the people who are selling Eli Lilly are very misplaced about how much this drug is going to matter, particularly because it really leapfrogged well over Novo Nordis. So short. When I finished this book, and when you read these books, they typically, people come on your show, people don't read the book, I read every page. And this book is, in many ways, it's about how to live longer, how to stay young, GOP-1, probably the number one way.

SPEAKER_3 (2:23)

So you're interested in buying Lilly down here? Yes, very much so. Very much so.

Jim Cramer (2:26)

Because people are selling it, they don't know what it is. They're just saying it's another drug, they're saying the government's cracking down. What they don't realize is worldwide, it's just a pretty long story. Worldwide, people are going to recognize that this is a different sort of drug. It's a drug that saves, that puts years on your life. That's very different. It's what put years on your life. And people who don't have anything wrong, you know, if you have co-morbidity, you have to take it. Anything that's co-morbidity, any drug that raises your weight, you're going to take this. Very, very significant.

Join the CNBC Investing Club with Jim Cramer to catch my member exclusive morning minis every day at 10, 20 a.m. Visit cnbc.com/morningtake to become a member today. That's one word, morning take.

SPEAKER_6 (3:15)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBC Universal or their parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

Conan O'Brien (3:58)

Hey everybody, Conan O'Brien here with an ad about my podcast, Conan O'Brien Needs a Friend. I've had so many fantastic conversations with people I truly admire, people like Michelle Obama, Bruce Springsteen, Maya Rudolph, Tom Hanks. New episodes are out every Monday and we have a really good time. So subscribe and listen wherever you get your podcasts.